Filgrastim Completed Phase 1 / 2 Trials for Leukemia, Plasma Cell / Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT02220608Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma